DOI QR코드

DOI QR Code

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

  • Zeng, Yin-Duo (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) ;
  • Zhang, Li (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) ;
  • Liao, Hai (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) ;
  • Liang, Ying (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) ;
  • Xu, Fei (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) ;
  • Liu, Jun-Ling (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) ;
  • Dinglin, Xiao-Xiao (Department of Medical Oncology, Cancer Center, Sun Yat-sen University) ;
  • Chen, Li-Kun (Department of Medical Oncology, Cancer Center, Sun Yat-sen University)
  • Published : 2012.03.31

Abstract

Background: Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), is used both as a single drug and concurrently with whole brain radiotherapy (WBRT) the standard treatment for brain metastases (BM), and is reported to be effective in a few small studies of patients with BM from non-small-cell lung cancer (NSCLC). However, no study has compared the two treatment modalities. This retrospective analysis was conducted to compare the efficacy of gefitinib alone with gefitinib plus concomitant WBRT in treatment of BM from NSCLC. Methods: We retrospectively reviewed 90 patients with BM from NSCLC who received gefitinib alone (250mg/day, gefitinib group) or with concomitant WBRT (40Gy/20f/4w, gefitinib-WBRT group) between September 2005 and September 2009 at Sun Yat-Sen University Cancer Center. Forty-five patients were in each group. Results: The objective response rate of BM was significantly higher in gefitinib-WBRT group (64.4%) compared with gefitinib group (26.7%, P<0.001). The disease control rate of BM was 71.1% in gefitinib-WBRT group and 42.2% in gefitinib group (P=0.006). The median time to progression of BM was 10.6 months in gefitinib-WBRT group and 6.57 months in gefitinib group (P<0.001). The median overall survival(OS) of gefitinib-WBRT and gefitinib alone group was 23.40 months and 14.83 months, respectively (HR, 0.432, P=0.002). Conclusion: Gefitinib plus concomitant WBRT had higher response rate of BM and significant improvement in OS compared with gefitinib alone in treatment of BM from NSCLC.

References

  1. Bianco C, Tortora G, Bianco R, et al (2002). Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res, 8, 3250-8.
  2. Bonner JA, Harari PM, Giralt J, et al (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354, 567-78. https://doi.org/10.1056/NEJMoa053422
  3. Ceresoli GL, Cappuzzo F, Gregorc V, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol, 15, 1042-7. https://doi.org/10.1093/annonc/mdh276
  4. Das AK, Sato M, Story MD, et al (2006). Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res, 66, 9601-8. https://doi.org/10.1158/0008-5472.CAN-06-2627
  5. Das AK, Chen BP, Story MD, et al (2007). Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res, 67, 5267-74. https://doi.org/10.1158/0008-5472.CAN-07-0242
  6. Fidler IJ, Yano S, Zhang RD, et al (2002). The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol, 3, 53-7. https://doi.org/10.1016/S1470-2045(01)00622-2
  7. Furuse K, Kamimori T, Kawahara M, et al (1997). A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in nonsmall- cell lung cancer with brain metastasis. Br J Cancer, 75, 614-8. https://doi.org/10.1038/bjc.1997.108
  8. Gow CH, Chien CR, Chang YL, et al (2008). Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res, 14, 162-8. https://doi.org/10.1158/1078-0432.CCR-07-1468
  9. Heimberger AB, Learn CA, Archer GE, et al (2002). Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFRtyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res, 8, 3496-502.
  10. Hotta K, Kiura K, Ueoka H, et al (2004). Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer, 46, 255-61. https://doi.org/10.1016/j.lungcan.2004.04.036
  11. Huang SM, Li J, Armstrong EA, et al (2002). Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res, 62, 4300-6.
  12. Jackman DM, Holmes AJ, Lindeman N, et al (2006). Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol, 24, 4517-20. https://doi.org/10.1200/JCO.2006.06.6126
  13. Kim JE, Lee DH, Choi Y, et al (2009). Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer, 65, 351-4. https://doi.org/10.1016/j.lungcan.2008.12.011
  14. Ma S, Xu Y, Deng Q, et al (2009). Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer, 65, 198-203. https://doi.org/10.1016/j.lungcan.2008.10.028
  15. Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. https://doi.org/10.1056/NEJMoa0810699
  16. Moscetti L, Nelli F, Felici A, et al (2007). Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer, 109, 274-81. https://doi.org/10.1002/cncr.22399
  17. Namba Y, Kijima T, Yokota S, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer, 6, 123-8. https://doi.org/10.3816/CLC.2004.n.026
  18. Nussbaum ES, Djalilian HR, Cho KH, et al (1996). Brain metastases. Histology, multiplicity, surgery, and survival. Cancer, 78, 1781-8. https://doi.org/10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-U
  19. Olak J (1999). Surgical strategies for metastatic lung cancer. Surg Oncol Clin N Am, 8, 245-57.
  20. Park SY, Kim YM, Pyo H (2010). Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol Cancer, 9, 222. https://doi.org/10.1186/1476-4598-9-222
  21. Quantin X, Khial F, Reme-Saumon M, et al (1999). Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer, 26, 35-9. https://doi.org/10.1016/S0169-5002(99)00071-9
  22. Shimato S, Mitsudomi T, Kosaka T, et al (2006). EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol, 8, 137-44. https://doi.org/10.1215/15228517-2005-002
  23. Shukuya T, Takahashi T, Naito T, et al (2011). Continuous EGFRTKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer, 74, 457-61. https://doi.org/10.1016/j.lungcan.2011.04.007
  24. Takahashi H, Ohrui T, Ebihara S, et al (2004). Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer, 43, 371-2. https://doi.org/10.1016/j.lungcan.2003.09.017
  25. van VM, Kal HB, Taphoorn MJ, et al (2002). Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review). Oncol Rep, 9, 683-8.
  26. Yawn BP, Wollan PC, Schroeder C, et al (2003). Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med, 86, 32-7.

Cited by

  1. Innovative Therapeutic Strategies in the Treatment of Brain Metastases vol.14, pp.1, 2013, https://doi.org/10.3390/ijms14012135
  2. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer vol.120, pp.2, 2014, https://doi.org/10.1007/s11060-014-1570-7
  3. Multiplex Real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for Prediction of Response of Non-small Cell Lung Cancer to Chemoradiotherapy vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4153
  4. A Systematic Review of Risk Factors for Brain Metastases and Value of Prophylactic Cranial Irradiation in Non-Small Cell Lung Cancer vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1233
  5. The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma vol.124, pp.1, 2015, https://doi.org/10.1007/s11060-015-1776-3
  6. Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1901
  7. A New Tool to Predict Survival after Radiosurgery Alone for Newly Diagnosed Cerebral Metastases vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2967
  8. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma vol.107, pp.12, 2016, https://doi.org/10.1111/cas.13079
  9. Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung vol.13, pp.5, 2016, https://doi.org/10.1111/ajco.12576
  10. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan vol.33, pp.1, 2016, https://doi.org/10.1007/s12032-015-0714-8
  11. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis vol.33, pp.8, 2016, https://doi.org/10.1007/s12032-016-0811-3
  12. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis vol.5, pp.6, 2016, https://doi.org/10.1002/cam4.673
  13. Stereotactic radiosurgery for small brain metastases and implications regarding management with systemic therapy alone vol.134, pp.2, 2017, https://doi.org/10.1007/s11060-017-2519-4
  14. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice vol.38, pp.2, 2017, https://doi.org/10.1038/aps.2016.107
  15. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer vol.51, pp.1, 2017, https://doi.org/10.1590/1414-431x20176073
  16. Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy pp.1569-8041, 2017, https://doi.org/10.1093/annonc/mdx408
  17. LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases vol.94, pp.5, 2015, https://doi.org/10.1097/MD.0000000000000375
  18. gene mutations and EGF receptor tyrosine kinase inhibitors vol.11, pp.16, 2015, https://doi.org/10.2217/fon.15.156
  19. Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors vol.32, pp.6, 2018, https://doi.org/10.1007/s40263-018-0526-4
  20. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease vol.13, pp.3, 2018, https://doi.org/10.1007/s11523-018-0566-1
  21. mutation-positive NSCLC: which tyrosine kinase inhibitor and when? vol.14, pp.11, 2018, https://doi.org/10.2217/fon-2017-0636